Midatech forms PharMida, a new life science subsidiary
月曜日, 17.11.2008

Midatech forms PharMida, a new life science subsidiary

Midatech Group, a world leader in nanotechnology, today announces the formation of a Basel-based Swiss drug development subsidiary, PharMida AG.

The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will have the responsibility to project manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage the rich collection of the already existing and most promising Midatech Ltd products or product lines in Life Sciences. PharMida will be headed by Professor Fritz R. Buhler as Chairman, and Dr Jan Mous as CEO.

 

Professor Fritz Buhler, Chairman of PharMida, is Professor of Pharmaceutical Medicine and Pathophysiology as well as of Internal Medicine and Cardiology at the Faculty of Medicine, Universities of Basel.
Dr Jan Mous, PharMida's new CEO, has a strong background in research and development, and many years' experience at senior level in a number of biotech companies. Most recently Dr Mous was President and CEO of IntegraGen, and prior to that he held the position of CSO and was member of the Executive Board of LION bioscience. From 1985 to 2000, Dr Mous enjoyed a successful career at F. Hoffmann-La Roche in Basel.
www.midatechgroup.com

 

For more information:
Jan Mous, PhD
CEO
PharMida AG
Hirschgässlein 11
CH-4010 Basel
Tel. +41-79-352 23 14
jan.mousanti spam bot@teleportanti spam bot.ch

 

 

<- Back to: Business Development and Life Science News in Basel, Switzerland